Heron Therapeutics, Inc. develops and commercializes therapies for acute care and oncology patients. Its product portfolio includes SUSTOL® for chemotherapy-induced nausea and vomiting, CINVANTI® for chemotherapy-induced nausea and vomiting, ZYNRELEF® for postoperative pain management, and APONVIE® for postoperative nausea and vomiting. The company focuses on addressing unmet medical needs through its patented technologies and drug development efforts.
